MENLO PARK, Calif., May 14 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing clinical systems for Enabling Regenerative Medicine(TM), announced today that it has been awarded a National Institutes of Health Phase I Small Business Innovation Research (SBIR) Grant entitled "Adult Stem Cell Minimally Invasive Bone Marrow Harvester." The award is to further develop the MarrowMiner(TM) which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for harvesting bone marrow.
"We are pleased to have been awarded this grant," commented Vartan Ghazarossian, PhD, President and CEO of StemCor Systems, Inc. "This SBIR award provides further validation of our scientific and clinical approach, to satisfy the unmet need to easily and effectively obtain marrow-derived cells. The grant will be used to broaden our capabilities regarding the harvest of bone marrow, as well as the processing of stem and progenitor cells it contains, for bone marrow transplantation. Additionally," he explained, "the MarrowMiner System has the potential to improve upon a growing number of therapeutic applications in the field of Regenerative Medicine including cardiovascular, neurologic, diabetic and orthopedic disorders."
About the MarrowMiner
The proprietary MarrowMiner System is designed to rapidly and easily harvest stem cell-rich bone marrow in a minimally-invasive manner, in the outpatient setting, and without general anesthesia. This is in contrast to the current practice of bone marrow aspiration through the insertion of a large gauge needle into multiple sites of the iliac crest of the hip, which usually requires general anesthesia, an operating room, and multiple clinical personnel, and results in marrow highly diluted with peripheral blood. Preclinical studies demonstrate that the MarrowMiner can safely harvest large volumes of marrow with significantly higher stem cell activity than is obtained with marrow harvested by means of standard needle aspirates.
About Bone Marrow
Bone marrow is a rich source of both adult stem and progenitor cells. Marrow-derived stem cells have been utilized extensively for over 40 years in the field of bone marrow transplantation, primarily for the treatment of a wide array of cancers and hematologic diseases for which over 60,000 transplants are performed each year. Orthopedic procedures, such as spinal fusions and the treatment of non-union fractures, also commonly utilize the patient's own bone marrow. More recently, marrow-derived cells are showing promise in the treatment of a widening array of diseases and conditions.
About Regenerative Medicine
Regenerative medicine focuses on the ability to repair or regenerate damaged, diseased or aging tissues, and is rapidly emerging as the next frontier in medicine. Regenerative therapies have the potential to provide effective treatment for millions of patients worldwide suffering from a wide array of diseases, including cardiovascular, endocrine (i.e. diabetes), neurologic, and orthopedic diseases. A critical aspect of many regenerative therapies is the ability to utilize the patient's own stem and progenitor cells, requiring the harvest, processing, and delivery of these cells to a target organ.
StemCor Systems is a privately held medical device company located in
the San Francisco Bay Area developing enabling technologies for
regenerative medicine. The company's initial product is the MarrowMiner, a
proprietary, minimally-invasive bone marrow collection system. The
technology was invented by Daniel Kraft, MD, and was licensed exclusively
from Stanford University. Clinical studies are now underway to evaluate the
potential of the MarrowMiner System to obtain sufficient and high quality
Contact: Vartan Ghazarossian, PhD
President and CEO
StemCor Systems, Inc.
|SOURCE StemCor Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved